Executive Series: Virtus Health (VRT) CEO, Sue Channon

 In this short video we discuss VRTs’ full year results, which saw NPAT attributable to ordinary equity holders down 14.6% to $28.1m and included a final dividend 12 cents per share fully franked; VRT’s position in the domestic market where it remains the overall leader with 42.1% share of the Australian eastern states market; The importance of VRT’s diagnostic business where revenue increased by nearly 9% in FY17, delivering an EBITDA improvement over the prior year of 37% driven by the new applications of genetic testing and screening in reproductive medicine.